[HTML][HTML] Клинико-иммунологическая характеристика постковидного периода у пациентов со среднетяжелым течением COVID-19, получавших терапию с …

ЛП Сизякина, НА Скрипкина, ЕА Антонова… - …, 2022 - cyberleninka.ru
Введение. Значительный прогресс в клинических исследованиях привел к лучшему
пониманию патогенеза COVID-19, способствуя его более эффективной терапии …

[HTML][HTML] SARS-CoV-2 and Therapeutic Approaches

D Chugh, M Bishnoi - The Open COVID Journal, 2022 - opencovidjournal.com
Abstract In 2019, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) was
first reported in Wuhan, China, affecting the population all over the globe. This ongoing …

[PDF][PDF] Uso de tocilizumab en pacientes con SARS-CoV-2 en el Hospital Nacional Dos de Mayo–Lima, año 2020

KC Pérez, MC Figueroa - Ciencia e …, 2022 - revistasinvestigacion.unmsm.edu.pe
Objetivo: Determinar las características del uso de tocilizumab (TCZ) en pacientes
hospitalizados por SARS-CoV-2, del Hospital Nacional Dos de Mayo de abril a setiembre …

SARS-CoV-2 Omicron infection in a cohort of hospitalized kidney transplant recipients: Risk factors of severity.

Z Cai, T Wang - Clinical Nephrology, 2024 - europepmc.org
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron is a
major coronavirus variant, which was prevalent in China at the end of 2022 and caused …

Solução numérica da dinâmica temporal da infecção do SARS-CoV-2 em pacientes com manifestações clínicas grave ou crítica da COVID-19

JAJ Avila, VM de Freitas - REMAT: Revista Eletrônica da …, 2023 - periodicos.ifrs.edu.br
A COVID-19 é uma doença infecciosa causada pelo coronavírus SARS-CoV-2, que
começou em Wuhan (China), no final de 2019, e se espalhou por todo o mundo. Quando o …

PROPOLIS AND COVID-19 INFECTION

G Sezgin, ZG Özünal - COVID-19 and Nutraceuticals, A …, 2021 - books.google.com
The word “propolis” has been derived from Greek;“Pro” that means “front” and “polis” that
means the beehive or city (Bankova et al., 2019). Propolis (bee glue) is produced by honey …

Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological Malignancies

F Cogliati Dezza, E Binetti, A Pupo, F Cancelli… - Available at SSRN … - papers.ssrn.com
During the SARS-CoV-2 pandemic, it has been rapidly clear that patients suffering from
haematological malignancies seem to present a more severe infection, higher mortality …

[PDF][PDF] Response of Tocilizumab in Treating Severe to Critical COVID-19; Single-Centre Experience at a Tertiary Care Centre

S Khan, MM Atif, S Asif, U Malik, S Zahoor, S Firdous - pafmj.org
Objective: To study the effectiveness of Tocilizumab in reducing mortality in severely or
critically ill patients. Study Design: Quasi-experimental study Place and Duration of Study …

[PDF][PDF] КЛИНИКО-ФАРМАКОЛОГИЧЕСКОЕ ОБОСНОВАНИЕ АНТИЦИТОКИНОВОЙ ТЕРАПИИ ПРИ ИНФЕКЦИИ SARS-CoV-2

Цель работы. На основании новейших литературных данных проанализировать
возможности применения в реальной врачебной практике новых подходов к лечению …

[PDF][PDF] Turnitin-The role of CD4+, CD8+, CD4+ _CD8+ and neutrophile to lymphocyte ratio in predicting and determining COVID-19 severity in Indonesian patients

DAPS Masyeni - repository.warmadewa.ac.id
Background: Biomarkers that are cost-effective and accurate for predicting severe
coronavirus disease 2019 (COVID-19) are urgently needed. We would like to assess the …